When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation

Authors: Weatherall J, Polonsky WH, Lanar S, Knoble N, Håkan-Bloch J, Constam E, Philis-Tsimikas A, Marrel A

Abstract

Background: Anecdotal reports suggest that insulin degludec (IDeg) may offer unique health-related quality of life (HRQoL) benefits. As the nature of these benefits remain unclear, this study utilized qualitative research methods to investigate and elucidate the experience of “feeling better” after initiating IDeg.

Methods: Twenty adults with type 2 diabetes (T2D) who reported “feeling better” on IDeg for > 3 months participated in 90-min interviews. One focus group and nine telephone interviews were conducted at two sites in the United States (US) and one focus group was conducted in Switzerland. Patients were ≥ 18 years of age, did not take mealtime insulin, and had switched to IDeg from another basal insulin. Discussions were audio-recorded, transcribed and translated (Swiss German). Utilizing grounded theory, transcripts were analyzed by sorting quotes into concepts using thematic analysis.

Results: Participants’ mean age was 66 years and the average duration of T2D was 17.6 years. Mean duration of IDeg use was 1.45 years. Four major factors were identified as key contributors to patients’ sense of “feeling better”: 1) reduced sense of diabetes as burdensome and requiring excessive attention; 2) enhanced feelings of adaptability and freedom; 3) heightened sense of security, especially regarding concerns about hypoglycemia; and 4) greater sense of physical well-being (greater energy/less fatigue). Content saturation was achieved. Generally, patients from the US sites were more focused on medical results than Swiss patients, who were more likely to identify IDeg’s effect on overall HRQoL. A limitation of the study was that the population was primarily white, > 60 and otherwise healthy (no comorbid physical or mental condition).

Conclusions: A group of patients with T2D, who had switched to IDeg from another basal insulin, reported HRQoL benefits which were attributed to both diabetes-specific improvements (feeling less burdened by day-to-day diabetes demands) and non-specific gains (greater energy). The conclusions may have limited transferability due to the characteristics of the sample population and further research is needed.

Source: https://pubmed.ncbi.nlm.nih.gov/29720273/

Share the Post:

BDI Monthly Events

May 7OMEGA Conference
May 7: As a keynote speaker at OMEGA, the First International Conference on Once-Weekly Glycated Albumin Monitoring for Diabetes, Dr. Polonsky (BDI President) will be presenting on “Glucose Monitoring and Behavior Change” (Tokyo, Japan).
May 14Case Consultation
May 14: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
May 18T1D Meet Up
May 18: Time for another T1D meet-up! Our friends and colleagues at GrownupT1Ds, a wonderful nonprofit here in southern California, is organizing another fun social event for adults with type 1 diabetes. This time it is a Walk, Talk & Picnic, and it begins at 11 am at the Bommer Canyon Trail (1 Sunnyhill, Irvine, CA). 92084. This event is free, but please RSVP Kelly Daes at www.grownupt1ds.org.
May 23SITEC 2025
May 23: Dr. Polonsky will be presenting (virtually) on “Far Beyond Time in Range: Exploring the Promises and Limitations of CGM” at SITEC 2025, Innovation and Technology Transforming Diabetes Care (Sao Paolo, Brazil). https://sitec.diabetes.org.br/